oasis trial semaglutide Novo Nordisk's of oral meets primary endpoint Low Dose Oral Semaglutide for

DNAm clocks did not uniformly decline in this long-term cohort, consistent with the papers finding that significant DNAm clock reductions were observed only in the hippocampus of the older, short-term treatment cohort

The compiled evidence was discussed during the second virtual meeting, and additional references were incorporated based on panel recommendations

Methods Using the JBI Manual for Evidence Synthesis 2024, a scoping review of existing literature for adults who are active or retired United Stated military with cLBP and other spine conditions, stratified by BMI and treatment interventions (surgical or other) as our cohort that contained any mention of BMI and quality of life outcomes, including validated PROMs, HRQoL domains and single item questions

Cell Biosci